Cargando…
Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Wolters Kluwer - Medknow
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557064/ https://www.ncbi.nlm.nih.gov/pubmed/31198676 http://dx.doi.org/10.4103/tjo.tjo_10_19 |
| _version_ | 1783425416037400576 |
|---|---|
| author | Schechet, Sidney A. Rodriguez, Sarah Hilkert Shapiro, Michael J. Blair, Michael P. |
| author_facet | Schechet, Sidney A. Rodriguez, Sarah Hilkert Shapiro, Michael J. Blair, Michael P. |
| author_sort | Schechet, Sidney A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6557064 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Wolters Kluwer - Medknow |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-65570642019-06-13 Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity” Schechet, Sidney A. Rodriguez, Sarah Hilkert Shapiro, Michael J. Blair, Michael P. Taiwan J Ophthalmol Author Reply Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6557064/ /pubmed/31198676 http://dx.doi.org/10.4103/tjo.tjo_10_19 Text en Copyright: © 2019 Taiwan J Ophthalmol http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
| spellingShingle | Author Reply Schechet, Sidney A. Rodriguez, Sarah Hilkert Shapiro, Michael J. Blair, Michael P. Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity” |
| title | Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity” |
| title_full | Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity” |
| title_fullStr | Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity” |
| title_full_unstemmed | Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity” |
| title_short | Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity” |
| title_sort | reply to comment on: “advantages of bevacizumab for aggressive posterior retinopathy of prematurity” |
| topic | Author Reply |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6557064/ https://www.ncbi.nlm.nih.gov/pubmed/31198676 http://dx.doi.org/10.4103/tjo.tjo_10_19 |
| work_keys_str_mv | AT schechetsidneya replytocommentonadvantagesofbevacizumabforaggressiveposteriorretinopathyofprematurity AT rodriguezsarahhilkert replytocommentonadvantagesofbevacizumabforaggressiveposteriorretinopathyofprematurity AT shapiromichaelj replytocommentonadvantagesofbevacizumabforaggressiveposteriorretinopathyofprematurity AT blairmichaelp replytocommentonadvantagesofbevacizumabforaggressiveposteriorretinopathyofprematurity |